Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease

Journal of Infectious Diseases

Volumn 197, Issue 1, 2008, Pages 25-33

  La Rosa, Corinna ^a   Krishnan, Aparna ^a   Longmate, Jeff ^a   Martinez, Joy ^a   Manchanda, Pooja ^a   Lacey, Simon F ^a   Limaye, Ajit P ^b   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD8 ANTIGEN; GANCICLOVIR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROGRAMMED DEATH 1 RECEPTOR; TETRAMER; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; LIVER GRAFT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIREMIA; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MIDDLE AGED; PROGNOSIS; UP-REGULATION; VIREMIA;

EID: 39349110212     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/523652     Document Type: Article

References (43)

1. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
2. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645-52.
3. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78:1390-6.
4. Boeckh M, Riddell SR. Immunologic predictors of late cytomegalovirus disease after solid organ transplantation - an elusive goal? J Infect Dis 2007; 195:615-7.
5. Greenberg PD, Riddell SR. Deficient cellular immunity - finding and fixing the defects. Science 1999; 285:546-51.
6. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195:633-44.
7. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-9.
8. Lacey SF, La Rosa C, Zhou W, et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis 2006; 194:1410-21.
9. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203:2281-92.
10. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-202.
11. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-4.
12. Urbani S, Amadei B, Tola D, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80:11398-403.
13. Boettler T, Panther E, Bengsch B, et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 2006; 80:3532-40.
14. Velu V, Kannanganat S, Ibegbu C, et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 2007; 81:5819-28.
15. Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52:165-73.
16. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77:5226-40.
17. La Rosa C, Wang Z, Lacey SF, et al. Characterization of host immunity to cytomegalovirus pp150 (UL32). Hum Immunol 2005; 66:116-26.
18. Lacey SF, Gallez-Hawkins G, Crooks M, et al. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002; 74:722-32.
19. Herzenberg LA, Tung J, Moore WA, Herzenberg LA, Parks DR. Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol 2006; 7:681-5.
20. Goepfert PA, Bansal A, Edwards BH, et al. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol 2000; 74:10249-55.
21. Ozdemir E, St John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8 T cells. Blood 2002; 100:3690-7.
22. Kostense S, Vandenberghe K, Joling J, et al. Persistent numbers of tetramer+ CD8+ T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood 2002; 99:2505-11.
23. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239-45.
24. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-7.
25. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-85.
26. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169:1984-92.
27. POS lymphocyte dynamics in primary CMV infection. Transplant Proc 2001; 33:1867-9.
28. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101:2686-92.
29. Shlobin OA, West EE, Lechtzin N, et al. Persistent cytomegalovirus- specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006; 176:2625-34.
30. Van Zanten J, Harmsen MC, van der MP, et al. Proliferative T cell responses to four human cytomegalovirus-specific proteins in healthy subjects and solid organ transplant recipients. J Infect Dis 1995; 172:879-82.
31. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180:247-53.
32. Singhal S, Shaw JC, Ainsworth J, et al. Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. Transplantation 2000; 69:2251-9.
33. Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71:1287-94.
34. Singh N, Gayowski T, Wagener MM, Zeevi A. T-helper cell responses in liver transplant recipients: correlation with cytomegalovirus and other major infections. Transpl Infect Dis 2004; 6:93-6.
35. Radha R, Jordan S, Puliyanda D, et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005; 5:110-7.
36. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201:1031-6.
37. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6:2356-64.
38. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25:757-63.
39. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19:1111-6.
40. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407-14.
41. Revello MG, Zavattoni M, Baldanti F, Sarasini A, Paolucci S, Gerna G. Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. J Clin Virol 1999; 14:57-66.
42. Gibson L, Piccinini G, Lilleri D, et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 2004; 172:2256-64.
43. Kim WR, Badley AD, Wiesner RH, et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 2000; 69:357-61.